StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
8
Publishing Date
2022 - 09 - 13
1
2021 - 12 - 27
1
2021 - 12 - 15
1
2021 - 10 - 18
1
2021 - 07 - 30
1
2021 - 06 - 25
1
2021 - 04 - 09
1
2021 - 03 - 30
1
Sector
Health technology
8
Tags
Abbvie
3
Alliances
10
Alzheimer
3
Alzheimer's
3
Alzheimer’s
3
Anti-cd40
3
Antibody
37
Approval
8
Asco
3
Asia
7
Award
4
Biocapital
23
Biopharma
5
Biotech
3
Biotech-bay
3
Biotech-beach
3
Biotechnology
8
Business
6
Cancer
17
Cd47
9
Cd73
3
China
25
Clinical-trials-phase-ii
13
Clinical-trials-phase-iii
3
Collaboration
5
Companies
4
Conference
10
Deal
4
Drug
11
Events
6
Expected
4
Fda
5
Financial
11
Financial results
8
Global
4
Growth
9
Ipo
4
Market
8
N/a
81
Nephropathy
4
Partnership
6
People
5
Pharmaceuticals
11
Phase 1
11
Phase 2
26
Phase 3
9
Positive
9
Pre-clinical
4
Preclinical
4
Presentation
5
Product-news
6
Report
10
Research
13
Results
27
Solid tumors
8
Study
5
Therapy
6
Treatment
8
Trial
21
Update
7
Entities
I-mab
8
Macrogenics, inc.
1
Morphosys ag
1
Sorrento therapeutics, inc.
1
Symbols
ABBV
37
ABT
24
ADCT
19
ADMA
17
AGIO
11
ALNY
13
AMGN
22
AMPH
9
AMRX
15
ANIP
17
ARGX
10
ARVL
14
ATLC
8
AVEO
20
BCRX
16
BGNE
24
BHC
8
BIIB
20
BMY
48
BPMC
23
BSX
8
CALT
8
CLVS
19
CNSP
11
EPZM
18
EXEL
14
FNCTF
21
FRG
15
GH
12
GILD
16
GSK
10
HALO
9
ILMN
12
IMAB
8
INCY
41
JAGX
8
JAZZ
8
JNJ
94
KMDA
11
KPTI
31
LLY
46
LTUM
11
MDT
28
MRK
8
NVAX
10
NVS
21
NVSEF
13
PFE
31
PRGO
21
REGN
32
RETA
9
RIGL
11
SNY
97
SNYNF
63
TAK
20
TEVJF
13
VRTX
8
VSTM
10
VTRS
8
YMAB
19
Exchanges
Nasdaq
8
Crawled Date
2022 - 09 - 13
1
2021 - 12 - 27
1
2021 - 12 - 15
1
2021 - 10 - 18
1
2021 - 07 - 30
1
2021 - 06 - 25
1
2021 - 04 - 09
1
2021 - 03 - 30
1
Crawled Time
12:00
1
12:15
2
13:00
1
13:20
1
14:00
1
15:30
1
20:00
1
Source
www.biospace.com
4
www.globenewswire.com
2
www.prnewswire.com
2
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Approval
symbols :
Imab
save search
I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome
Published:
2022-09-13
(Crawled : 13:20)
- biospace.com/
IMAB
|
$1.795
-0.83%
-0.84%
140K
|
Health Technology
|
-67.74%
|
O:
-2.33%
H:
0.72%
C:
-0.73%
approval
china
study
I-Mab Announces IND Approval from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors
Published:
2021-12-27
(Crawled : 14:00)
- biospace.com/
MGNX
|
$16.08
-0.12%
-0.12%
590K
|
Health Technology
|
-7.36%
|
O:
-0.75%
H:
1.28%
C:
-2.84%
IMAB
|
$1.795
-0.83%
-0.84%
140K
|
Health Technology
|
-96.16%
|
O:
-0.49%
H:
2.25%
C:
-0.79%
phase 2
solid tumors
trial
approval
china
I-Mab Receives IND Approval for Phase 1 Clinical Trial of Bispecific Antibody TJ-CD4B in Solid Tumors in China
Published:
2021-12-15
(Crawled : 15:30)
- biospace.com/
IMAB
|
$1.795
-0.83%
-0.84%
140K
|
Health Technology
|
-96.36%
|
O:
-11.41%
H:
8.08%
C:
7.32%
solid tumors
trial
approval
phase 1
china
antibody
phase 2
I-Mab Announces IND Approval for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China
Published:
2021-10-18
(Crawled : 12:00)
- prnewswire.com
IMAB
|
$1.795
-0.83%
-0.84%
140K
|
Health Technology
|
-97.28%
|
O:
-1.19%
H:
4.34%
C:
2.66%
phase 2
china
therapy
trial
approval
I-Mab Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for the Treatment of Alzheimer's Disease
Published:
2021-07-30
(Crawled : 12:15)
- prnewswire.com
IMAB
|
$1.795
-0.83%
-0.84%
140K
|
Health Technology
|
-97.64%
|
O:
-2.28%
H:
0.0%
C:
0.0%
disease
alzheimer
treatment
fda
phase 1
approval
phase 2
phase 3
alzheimer’s
alzheimer's disease
alzheimer's
I-Mab Announces China NMPA Approval for Phase 1b Trial of Felzartamab in Systemic Lupus Erythematosus
Published:
2021-06-25
(Crawled : 13:00)
- biospace.com/
MOR
|
$18.02
-0.11%
-0.11%
590K
|
Health Technology
|
-6.81%
|
O:
2.89%
H:
0.23%
C:
-0.55%
IMAB
|
$1.795
-0.83%
-0.84%
140K
|
Health Technology
|
-97.79%
|
O:
-3.4%
H:
3.67%
C:
-0.65%
phase 1
china
trial
approval
lupus
phase 1b
phase 2b
Scilex Holding, a Subsidiary of Sorrento, Has Received From FDA a sNDA Approval for ZTlido® Label Expansion
Published:
2021-04-09
(Crawled : 20:00)
- globenewswire.com
SRNE
|
$0.028
-8.85%
42K
|
Health Technology
|
Email alert
Add to watchlist
IMAB
|
$1.795
-0.83%
-0.84%
140K
|
Health Technology
|
Email alert
Add to watchlist
fda
expansion
approval
I-Mab and ABL Bio Receive US FDA Approval to Initiate Phase 1 Trial of Bispecific Antibody TJ-CD4B/ABL111 in Patients with Advanced or Metastatic Solid Tumors
Published:
2021-03-30
(Crawled : 12:15)
- globenewswire.com
IMAB
|
$1.795
-0.83%
-0.84%
140K
|
Health Technology
|
-95.94%
|
O:
3.45%
H:
4.76%
C:
2.74%
fda
solid tumors
phase 1
fda approval
antibody
trial
approval
phase 3
phase 2
Gainers vs Losers
64%
36%
Top 10 Gainers
AGBA
|
News
|
$1.02
155.0%
57.94%
120M
|
Finance
ZCMD
|
$2.86
108.76%
52.1%
2.3M
|
Commercial Services
INVO
|
$1.555
104.6%
51.13%
5M
|
Health Technology
ISPC
|
$0.437
105.16%
49.53%
37M
|
Professional, Scientific, and T...
WLGS
|
News
|
$0.92
84.0%
45.65%
1.6M
|
OST
|
$0.499
21.38%
45.26%
1.9M
|
XPON
|
News
|
$3.1
60.62%
37.74%
17M
|
TIRX
|
$0.7
44.39%
30.74%
58M
|
BNTC
|
News
|
$6.92
44.17%
30.64%
3.5M
|
Health Technology
GGE
|
$0.035
19.86%
29.3%
64M
|
Your saved searches
Save your searches and get alerts when important news are released.